Why it matters now
The emergence of GLP-1 receptor agonists has revolutionized diabetes and weight management, significantly altering treatment paradigms. These medications can improve glycemic control and reduce insulin requirements for many patients, directly influencing the demand for traditional diabetes devices. Manufacturers of insulin pumps and continuous glucose monitors (CGMs) must understand how these powerful new drugs are shifting patient needs and market dynamics. Failing to adapt product development and commercial strategies could lead to reduced market share and missed opportunities in an evolving landscape. Proactive assessment is vital for sustained growth.
Who is exposed
Insulin pump manufacturers face potential reductions in demand if GLP-1s lead to fewer patients requiring intensive insulin therapy. Continuous glucose monitor companies may see shifts in user profiles or usage patterns. Diabetes management platforms must integrate with GLP-1 treatment plans and potentially adapt their algorithms. Pharmaceutical companies with existing diabetes portfolios are also exposed to competitive pressures and market shifts. Healthcare providers must adjust their treatment recommendations, impacting device prescriptions.
Most relevant for: Product Manager, Strategy Director, Investment Analyst
What this Viewpoint covers
- How are GLP-1s impacting insulin prescription rates for different patient types?
- What is the projected effect on demand for insulin pumps?
- How are CGM usage patterns evolving among patients on GLP-1s?
- Which new features or integrations are becoming critical for diabetes devices?
- How are patient education and support programs adapting to GLP-1 use?
Signals to watch
- Changes in insulin prescription volumes following GLP-1 adoption.
- Announcements of new clinical trials combining GLP-1s with device therapy.
- Product development focus by device manufacturers on 'smart' integration.
- Shifts in payer coverage for diabetes devices in conjunction with GLP-1s.
Decisions it supports
- How to adapt product development roadmaps for insulin pumps and CGMs.
- Which patient segments to target with specific device features.
- Whether to pursue partnerships with pharmaceutical companies developing GLP-1s.
How it is built
Prepared after your order from dated public sources - such as medical devices & healthcare filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
Will GLP-1 medications make insulin pumps obsolete?
It is unlikely that GLP-1 medications will make insulin pumps obsolete. While GLP-1s can reduce insulin needs for some, many patients will still require insulin, especially those with advanced Type 1 or Type 2 diabetes. The market may shift, with pumps potentially focusing on more complex cases or integrating with GLP-1 data for optimized management.
How will GLP-1s affect the demand for continuous glucose monitors?
The demand for continuous glucose monitors (CGMs) may evolve rather than diminish. CGMs remain valuable for monitoring glucose trends, even for patients on GLP-1s, to optimize medication dosing, understand dietary impacts, and prevent hypoglycemia. The focus might shift to integrating CGM data with GLP-1 treatment plans for holistic diabetes management.
What strategies should device manufacturers consider?
Device manufacturers should focus on innovation that enhances integration between devices and GLP-1 treatment, such as algorithms that adjust insulin delivery based on GLP-1 effects. Emphasizing the benefits of devices for personalized management, even alongside GLP-1s, and exploring new patient segments are also important strategies.